Catalyst

Slingshot members are tracking this event:

TESARO's Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO

100%
CLVS

100%

Additional Information

Additional Relevant Details
  • The NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort  
  • The NOVA trial successfully achieved its primary endpoint of PFS in the non-germline BRCA mutant cohort, including both the HRD-positive and overall analysis populations
  • NOVA is the first successful prospectively designed Phase 3 trial of a PARP inhibitor

    T
    he Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival (PFS). This trial demonstrated that niraparib significantly prolonged PFS compared to control among patients who are germline BRCA mutation (gBRCAmut) carriers, among patients who are not germline BRCA mutation (non-gBRCAmut) carriers but who have homologous recombination deficient (HRD) tumors as determined by the Myriad myChoice®HRD test, and overall in patients who are not germline BRCA mutation carriers.
http://ir.tesarobio....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 29, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Niraparib, Progression-free Survival, Ovarian Cancer, Nova Trial, Germline Brca Mutation, Homologous Recombination Deficient